Fosun Pharma gets rights to Dova's avatrombopag

The AkaRx Inc. subsidiary of Dova Pharmaceuticals Inc. (NASDAQ:DOVA) granted the Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. subsidiary of Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive development and commercialization rights in mainland China and Hong Kong to avatrombopag to treat chronic liver disease patients with thrombocytopenia.

AkaRx will receive an undisclosed upfront payment and is eligible for milestones. Fosun plans to develop the candidate in additional indications...